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BY-NC-ND license (http://creativecomAbstract Background/Purpose: Cancer stem cells (CSCs) are deemed as the driving force of
tumorigenesis in oral squamous cell carcinomas (OSCCs). In this study, we investigated the
chemotherapeutic effect of sulforaphane, a dietary component from broccoli sprouts, on tar-
geting OSCC-CSCs.
Methods: The effect of sulforaphane on normal oral epithelial cells (SG) and sphere-forming
OSCC-CSCs isolated from SAS and GNM cells was examined. ALDH1 activity and CD44 positivity
of OSCC-CSCs with sulforaphane treatment was assessed by flow cytometry analysis. In vitro
and in vivo tumorigenicity assays of OSCC-CSCs with sulforaphane treatment were presented.
Results: We observed that the sulforaphane dose-dependently eliminated the proliferation
rate of OSCC-CSCs, whereas the inhibition on SG cells proliferation was limited. Cancer stem-
ness properties including self-renewal, CD44 positivity, and ALDH1 activity were also
decreased in OSCC-CSCs with different doses of sulforaphane treatment. Moreover, sulforaph-
ane treatment of OSCC-CSCs decreased the migration, invasion, clonogenicity, and in vivo
tumorigenicity of xenograghts. Sulforaphane treatment resulted in a dose-dependent increase
in the levels of tumor suppressive miR200c.
Conclusion: These lines of evidence suggest that sulforaphane can suppress the cancer stem-
ness and tumor-initiating properties in OSCC-CSCs both in vitro and in vivo.
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42 C.-M. Liu et al.IntroductionOral squamous cell carcinoma (OSCC) is the sixth most
common cancer type worldwide with poor prognosis.1 Un-
fortunately, cancer therapies including extensive surgery,
radiotherapy, chemotherapy, or concurrent chemo/radio-
therapy are not effective for patients with advanced OSCC
because of tumor recurrence, metastasis, and poor
response to chemotherapy and radiotherapy.1 Epidemio-
logical evidence strongly indicates that OSCC is highly
associated with the areca quid chewing habit.2 Cancer stem
cells (CSCs), also known as tumor-initiating cells, comprise
a unique subpopulation of cells within a tumor.3 Relative to
the remaining the tumor bulk, CSCs are often more
tumorigenic and chemoresistant/radioresistant than the
tumor bulk.4 Previously, we have verified that oralspheres,5
CD133,6 aldehyde dehydrogenase (ALDH),7 membrane
GRP78,8 and side population9 could be the markers to
isolate and identify the CSCs from OSCC (OSCC-CSCs).
Therefore, it is imperative to develop strategies on tar-
geting CSCs.
Sulforaphane, first identified in broccoli sprouts, is well-
known for pleiotropic anticarcinogenic effect on a variety
of experimental cancer models including repression of
cancer cell proliferation, stimulation of cancer cell
apoptosis, and inhibition of tumor progression and meta-
stasis.10e13 Sulforaphane exerted an inhibitory effect on
the oncogenicity of cancer cells by modulating numerous
cell signaling pathways including Keap1eNrf2 signaling,14
mitogen-activated protein kinase pathway,15 and nuclear
factor kappa B signaling.16 Substantial evidence has
demonstrated that sulforaphane inhibited CSCs in breast
cancer,17 prostate cancer,18 and pancreatic cancer.19
However, the efficacy of sulforaphane on the specific sub-
set of OSCC-CSCs is still not clear.
In this study, we explore a chemotherapeutic effect of
sulforaphane on targeting OSCC-CSCs by intro and in vivo
xenograft mouse models. Strikingly, sulforaphane treat-
ment diminished cancer stemness and tumorigenicity both
in vitro and in vivo.
Methods
Cell culture and reagents
SAS or GNM cells were maintained in Dulbecco’s modified
Eagle medium (DMEM; Gibco Laboratories, Grand Island,
NY, USA) containing 10% fetal bovine serum (Gibco Labo-
ratories). Cells were grown at 37C in a humidified incu-
bator containing 5% CO2. Sulforaphane was purchased from
Sigma-Aldrich (St. Louis, MO, USA).
Enrichment of sphere-forming OSCC-CSCs
For enrichment of OSCC-CSCs, the two cell lines were
cultured in tumor sphere medium consisting of serum-free
DMEM/F12 medium (Gibco Laboratories), N2 supplement
(Gibco Life Technologies), 10 ng/mL human recombinant
basic fibroblast growth factor-basic (FGF) and 10 ng/mL
epidermal growth factor (EGF; R&D Systems, Minneapolis,
MN, USA). Cells were plated at a density of 103 live cells/low-attachment six-well plate (Corning Inc., Corning, NY,
USA), and the medium was changed every other day until
the tumor sphere formation was observed in about 2 weeks.
For serial passage of spheroid cells, single cells will be
obtained from accurtase-treated spheroids and the cell
density of passage will be 1000 cells/mL in the serum-free
medium as described above.8,20
Cell proliferation determination by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide assay
Cells were plated in 96-well plates (at 1  104 cells/well) in
0.1% dimethyl sulfoxide (DMSO) or different concentrations
of sulforaphane-containing medium and cultured at 37C
for 24 hours. Cell proliferation/survival was determined
using MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetra-
zolium bromide] assay. The 570-nm absorbance of the
DMSO-treated group was set as 100%, and data were pre-
sented as percentage of DMSO control.21
CD44 staining by flow cytometry analysis
Cells were stained with anti-CD44 antibody conjugated to
phycoerythrin (Miltenyi Biotech., Auburn, CA, USA), with
labeling according to the manufacturer’s instructions. Red
(> 650 nm) fluorescence emission from 10,000 cells illu-
minated with blue (488 nm) excitation light was measured
with a FACSCalibur (Becton Dickinson, Mountain View, CA,
USA) using CellQuest software.21
Cell migration and cell in invasion assay
Cell migration and cell in invasion assays were performed as
described previously.22
Soft agar colony forming assay
Six-well culture dish was coated with 2 mL bottom agar
(Sigma-Aldrich) mixture [DMEM, 10% (v/v) fetal calf
serum, 0.6% (w/v) agar]. After the bottom layer was so-
lidified, 2 mL top agaremedium mixture [DMEM, 10% (v/v)
fetal calf serum, 0.3% (w/v) agar] containing 2  104 cells
was added, and the dishes were incubated at 37C for
4 weeks. Plates were stained with 0.005% Crystal Violet,
and the colonies were counted. The number of total col-
onies with a diameter  100 mm was counted over five
fields per well for a total of 15 fields in triplicate
experiments.23
Effect of sulforaphane on tumor growth in nude
mice
All procedures involving animals were in accordance with
the institutional animal welfare guidelines of the Chung
Shan Medical University. For the nude mice xenograft
model, 5e6-week-old immunodeficient nude mice (BALB/c
nu/nu mice) weighing 18e22 g were used. The mice were
housed with a regular 12-hour light/12-hour dark cycle and
ad libitum access to standard rodent chow diet (Laboratory
Targeting oral cancer stem cells by sulforaphane 43Rodent Diet 5001; LabDiet, St. Louis, MO, USA) and were
kept in a pathogen-free environment at the Laboratory
Animal Unit. OSCC-CSCs (1  104 cells/0.2 mL/mouse) were
injected subcutaneously into the right front axilla. Eight
days after implantation, the mice were randomly divided
into two groups (NZ 6 for each group) and intaperitoneally
injected with vehicle (saline) or 50 mg/kg sulforaphane.
The volume was calculated according to the following
formula:24

lengthwidth22: ð1Þ
MicroRNA quantitative reverse transcription-
polymerase chain reaction analysis
For miR-200c levels detection, miRNA quantitative
reverse transcription-polymerase chain reaction (qRT-
PCR) was performed using TaqMan miRNA assays with
specific primer sets (Applied Biosystems, Foster City, CA,
USA). All reagents and protocols were obtained from
Applied Biosystems, and detection was performed using
a StepOne Plus real-time PCR system (Applied
Biosystems).22
Western blot assay
The extraction of proteins from cells and Western blot
analysis were performed as previously described.25 Sam-
ples (15 mL) were boiled at 95C for 5 minutes and sepa-
rated by 10% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis. The proteins were wet-transferred toFigure 1 Sulforaphane treatment suppresses the proliferation a
that concentration-dependent inhibition of cell viability in SG and O
assessed and presented as percent survival relative to untreated cel
were subjected to a self-renewal secondary sphere-forming assay.
The experiments were repeated three times, and representative
deviation. * p < 0.05 versus Control. CSC Z cancer stem cells;
bromide; OSCC Z oral squamous cell carcinomas.Hybond-ECL nitrocellulose paper (Amersham, Arlington
Heights, IL, USA). The following primary antibodies were
used: anti-human Bmi1 (Cell Signaling, Beverly, MA, USA)
and anti-b-actin (Millipore Corp., Billerica, MA, USA).
Immunoreactive protein bands were detected by the ECL
detection system (Amersham Biosciences Co., Piscataway,
NJ, USA).
Statistical analysis
SPSS (version 13.0; SPSS, Inc., Chicago, IL, USA) was used
for statistical analysis. The presented results are repre-
sentative of three independent experiments with similar
results. Statistical differences were evaluated using
Student t test and were considered significant at
p < 0.05.
Results
Effects of sulforaphane on the viability and self-
renewal ability in OSCC-CSCs
It has been reported that OSCC-CSCs can be cultured in
suspension to generate floating oralspheres under serum-
free medium with bFGF and EGF.5 We further examined the
cytotoxic activity of sulforaphane to sphere-forming OSCC-
CSCs from SAS and GNM. With the MTT assay, sulforaphane
treatment dose-dependently suppressed the proliferation
rate of OSCC-CSCs, whereas the inhibition on normal oral
epithelial cells (SG) proliferation was limited (Figure 1A).
Secondary tumorsphere-forming ability is a commonnd self-renewal properties of OSCC-CSCs. (A) MTT assay shows
SCC-CSCs by sulforaphane (24 hours) treatment. Cell survival is
ls. (B) Primary OSCC-CSCs treated with or without sulforaphane
The number of secondary spheres is calculated and presented.
results are shown. Results are presented as mean  standard
MTT Z 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
44 C.-M. Liu et al.method to observe self-renewal capability.24 We then
evaluated the potential role of sulforaphane in modulating
the self-renewal property of OSCC-CSCs, and found that
sulforaphane decreased the secondary sphere-forming
ability of OSCC-CSCs (Figure 1B).Sulforaphane represses ALDH1 activity and CD44
positivity in OSCC-CSCs
ALDH1 activity and CD44 expression have been demon-
strated to be markers for isolating as well as identifying the
putative OSCC-CSCs.26,27 Flow cytometry analysis of the
ALDH1 and CD44 expression patterns indicated that
sulforaphane-treated OSCC-CSCs dose-dependently
induced a reduction in ALDH1 activity (Figure 2A) and
CD44 positivity (Figure 2B) of OSCC-CSCs.Sulforaphane suppresses migration/invasion
capabilities of OSCC-CSCs
As high oncogenicity and metastasis are hallmarks of
CSCs,28 we sought to measure the effects of sulforaphane
on migration and invasion ability of OSCC-CSCs. Single-cell
suspensions of control- or sulforaphane-treated OSCC-
CSCs were used for analysis of their metastatic capacity
in vitro as described in the Methods section. Our data
indicate that sulforaphane dose-dependently inhibits theFigure 2 Effects of sulforaphane on CD44 and ALDH1 activity ex
activity of OSCC-CSCs treated with or without sulforaphane was
repeated three times, and representative results are shown. Result
Control. ALDH Z aldehyde dehydrogenase; CSC Z cancer stem cemigration (Figure 3A) and invasion (Figure 3B) abilities of
OSCC-CSCs.
Effects of sulforaphane on tumor initiation activity
in vitro and in vivo
We next examined whether the anchorage-independent
growth ability of OSCC-CSCs was influenced by sulforaphane
treatment. We have demonstrated that sulforaphane
significantly suppressed the cologenicity of OSCC-CSCs
(Figure 4A). Next, we explored the therapeutic potential
of sulforaphane in immunocompromised mice bearing
OSCC-CSCs xenograft tumors. Eight days after OSCC-CSCs
inoculation, OSCC-CSCs-transplanted nude mice were
intraperitoneally injected with 50 mg/kg sulforaphane. By
Day 20, sulforaphane treatment induced a reduction in
tumor volume of oral CSC-transplanted nude mice
(Figure 4B).
Sulforaphane treatment induced miR-200c
MicroRNAs (miRNAs) have been shown to be correlated
with several aspects of key players of cancer-related
hallmarks including cancer stemness.29 Previously, we
have demonstrated that miR200c regulated tumorige-
nicity in OSCC-CSCs by directly targeting Bmi1.30
Elevating miR-200c expression by natural compound ap-
pears to be a promising therapeutic modality to targetpression in OSCC-CSCs. The (A) CD44 positivity and (B) ALDH1
assessed by flow cytometry analysis. The experiments were
s are presented as mean  standard deviation. * p < 0.05 versus
lls; OSCC Z oral squamous cell carcinomas.
Figure 3 Effects of sulforaphane on migration and invasion ability in OSCC-CSCs. (A) Different concentrations of sulforaphane-
treated OSCC-CSCs were subjected to migration assay and matrix invasion assay. (B) The experiments were repeated three times,
and representative results are shown. Results are presented as mean  standard deviation. * p < 0.05 versus Control. CSCZ cancer
stem cells; OSCC Z oral squamous cell carcinomas.
Targeting oral cancer stem cells by sulforaphane 45OSCC-CSCs. To investigate the molecular mechanism of
sulforaphane in targeting cancer stemness, miR-200c
expression in sulforaphane-treated OSCC-CSCs was
determined by miRNA RT-PCR analysis. Sulforaphane
treatment resulted in a dose-dependent increase in the
levels of miR-200c in OSCC-CSCs (Figure 5A). Sulforaph-
ane treatment of OSCC-CSCs cells also suppressed the
protein levels of Bmi1, which were implicated as targets
of miR-200c (Figure 5B).
Discussion
A large number of studies have demonstrated that tumors
including OSCCs contain a crucial subset of cells, i.e., or
tumor-initiating cells, which exhibit a self-renewing ca-
pacity and have the ability to reform new tumors in vivo.3
CSCs are key contributors to radioresistance and are
responsible for tumor progression of OSCC as well as
recurrence after traditional chemotherapy. Therefore,
the search for approaches to target CSCs for OSCC
treatment may pave a way toward a new set of clinical
practices. In this study, we showed that sulforaphane, a
dietary component of broccoli/broccoli sprouts, elimi-
nated cancer stemness both in vitro and in vivo. Cancer
stemness including self-renewal capability, ALDH1 activ-
ity, CD44 positivity in OSCC-CSCs was significantlyinhibited by sulforaphane treatment. Moreover, sulfo-
raphane treatment repressed migration/invasiveness/
cologenicity and in vivo tumor growth in OSCC-CSCs. To
our knowledge, this is the first report to demonstrate that
suppression of cancer stemness could be partially
augmented by the anticarcinogenic effect of sulforaph-
ane in OSCC-CSCs.
miRNAs, a class of highly conserved small RNA mole-
cules regulating gene expression,31 has emerging roles
during carcinogenesis in various types of cancers.32e34
Genomic rearrangement located at locus near miRNA
clusters had been reported. A pair of neighboring miRNAs
is frequently deleted in human chronic lymphocytic leu-
kemia,35 and miRNA genes are either lost or amplified in
tumor.36 Conversely, the deletion and silencing of a gene
encoding a miRNA that normally suppress expression of
oncogenes might lead to increased protein expression and
a gain in oncogenic potency.37 miRNAs such as miR-21,38
miR-31,39 miR-504,40 miR-10b,41 let-7,20 or miR-18440
were revealed to be the most consistently deregulated
miRNAs in OSCC. Recently, natural compounds-regulated
miRNAs have been shown to be involved in the epige-
netic regulation of cancer stemness in several types of
malignant cancers. Our previous work has shown that miR-
200c-targeting Bmi1 is involved in the regulation of cancer
stemness in OSCC.30 The expression of miR-200c in OSCC
Figure 5 Sulforaphane treatment induces miR-200c expression in OSCC-CSCs. (A) miRNA real-time RT-PCR analysis was applied to
analyze the relative miR-200c expression level in sulforaphane dose-dependently treated OSCC-CSCs. (B) Western blotting was used
to assess the expression level of Bmi1 in OSCC-CSCs with sulforaphane treatment. The experiments were repeated three times, and
representative results are shown. Results are presented as mean  standard deviation. * p < 0.05 versus Control. CSC Z cancer
stem cells; miRNA Z microRNA; OSCC Z oral squamous cell carcinomas; RT-PCR Z reverse transcription-polymerase chain
reaction.
Figure 4 Effects of sulforaphane on CD44 and ALDH1 activity expression in OSCC-CSCs. (A) Colony-forming ability was assessed in
OSCC-CSCs dose-dependently treated with sulforaphane. (B) Effect of sulforaphane treatment on subcutaneous xenografts of
OSCC-CSCs in vivo (N Z 6 for each group). The experiments were repeated three times, and representative results are shown.
Results are presented as mean  standard deviation. * p < 0.05 versus Control. ALDH Z aldehyde dehydrogenase; CSC Z cancer
stem cells; OSCC Z oral squamous cell carcinomas.
46 C.-M. Liu et al.tissues is significantly decreased in tumor specimens.30 In
the study, sulforaphane treatment impaired tumor growth
in OSCC-CSC tumor-bearing mice through miR-200c in-
duction. These findings support the idea that miR-200ccould be potentially used as cancer signatures and thera-
peutic targets.
Conclusively, the present study showed that sulfo-
raphane inhibited cancer stemness through miR-200c in-
duction, which resulted in the inhibition of the self-
Targeting oral cancer stem cells by sulforaphane 47renewal, metastasis, and tumor initiation properties of
OSCC-CSCs. These findings provide a strong rationale for
the use of sulforaphane for OSCC chemoprevention and
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